HOME > 研究業績詳細

研究業績詳細

萩原 晋二(ハギワラ シンジ)

研究テーマ 糖尿病性腎症の病因学的研究
研究業績(論文) 1. Gohda T, Tanimoto M, Shiina K, Ito T, Kobayashi M, Hagiwara S, Kaneko S, Makita Y, Funabiki K, Horikoshi S, Tomino Y: Altered mouse cholinephosphotransferase gene expression in kidneys of type 2 diabetic KK/TA mouse. Metabolism 53:842-6, 2004, IF:5.777/CI:4
2. Hagiwara S, Ohi H, Eishi Y, Kodama F, Tashiro K, Makita Y, Suzuki Y, Maeda K, Fukui M, Horikoshi S, Tomino Y: A case of renal sarcoidosis with complement activation via the lectin pathway. Am J Kidney Dis 45:580-7, 2005, IF:7.623/CI:10
3. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y: Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 21:299-313, 2006, IF:4.47/CI:76
4. Hagiwara S, Makita Y, Gu L, Tanimoto M, Zhang M, Nakamura S, Kaneko S, Itoh T, Gohda T, Horikoshi S, Tomino Y: Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant 21:605-615, 2006, IF:4.47/CI:45
5. Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Murakoshi M, Aoki T, Wakabayashi M, Gohda T, Funabiki K, Maeda K, Horikoshi S, Tomino Y: Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 11:29-35, 2006, IF:1.563/CI:33
6. Zhang M, Hagiwara S, Matsumoto M, Gu L, Tanimoto M, Nakamura S, Kaneko S, Gohda T, Qian J, Horikoshi S, Tomino Y: Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress. Metabolism 55:1590-1598, 2006, IF:5.777/CI:19
7. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y: Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56:160-167, 2007, IF:5.777/CI:52
8. Hagiwara S, Saima S, Negishi K, Takeda R, Miyauchi N, Akiyama Y, Horikoshi S, Tomino Y: High incidence of renal failure in patients with aortic aneurysms. Nephrol Dial Transplant 22:1361-1368, 2007, IF:4.47/CI:18
9. Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Ohara I, Toyoda H, Ishikawa Y, Horikoshi S, Tomino Y: Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetes Res Clin Pract 83:183-189, 2009, IF:3.639/CI:9
10. Hagiwara S, Gohda T, Tanimoto M, Ito T, Murakoshi M, Ohara I, Yamazaki T, Matsumoto M, Horikoshi S, Funabiki K, Tomino Y: Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. Metabolism 58:934-945, 2009, IF:5.777/CI:15
11. Yamazaki T, Tanimoto M, Gohda T, Ohara I, Hagiwara S, Murakoshi M, Matsumoto M, Kaneko S, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y: Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice. Nephron Exp Nephrol 113:e66-76, 2009, IF:2.238/CI:15
12. Io H, Matsumoto M, Okumura K, Sato M, Masuda A, Furukawa M, Nohara N, Tanimoto M, Kodama F, Hagiwara S, Gohda T, Shimizu Y, Tomino Y: Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients. Semin Dial 24:349-354, 2011, IF:1.671/CI:11
13. Furukawa M, Io H, Tanimoto M, Hagiwara S, Horikoshi S, Tomino Y: Predictive factors associated with the period of time before initiation of hemodialysis in CKD stages 4 and 5. Nephron Clin Pract 117:c341-7, 2011, IF:2.138/CI:10
14. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y: Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp Nephrol 117:e124-132, 2011, IF:2.238/CI:22
15. Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Takagi M, Horikoshi S, Tomino Y: Mindin: a novel marker for podocyte injury in diabetic nephropathy. Nephrol Dial Transplant 26:2153-2160, 2011, IF:4.47/CI:9
16. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, Murakoshi M, Aoki T, Ishikawa Y, Lee SH, Jeong KH, Lee TW, Ihm CG, Lim SJ, Tomino Y: Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-Ay/Ta mice. Am J Physiol Renal Physiol 300:F1271-F1282, 2011, IF:3.611/CI:54
17. Aoki T, Kaneko S, Tanimoto M, Gohda T, Hagiwara S, Murakoshi M, Ishikawa Y, Furukawa M, Funabiki K, Horikoshi S, Tomino Y: Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice. J Nephrol 25:127-136, 2012, IF:2.153/CI:3
18. Ishikawa Y, Gohda T, Tanimoto M, Omote K, Furukawa M, Yamaguchi S, Murakoshi M, Hagiwara S, Horikoshi S, Funabiki K, Tomino Y: Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Exp Diabetes Res 2012:702948, 2012, IF:4.325/CI:14
19. Furukawa M, Gohda T, Hagiwara S, Tanimoto M, Horikoshi S, Funabiki K, Tomino Y: Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse. Int J Nephrol 2013:519130, 2013, IF:NA/CI:NA
20. Wang B, Jha JC, Hagiwara S, McClelland AD, Jandeleit-Dahm K, Thomas MC, Cooper ME, Kantharidis P: Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int 85:352-361, 2014, IF:8.395/CI:56
21. McClelland AD, Herman-Edelstein M, Komers R, Jha JC, Winbanks CE, Hagiwara S, Gregorevic P, Kantharidis P, Cooper ME: miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond) 129:1237-1249, 2015, IF:4.936/CI:34
22. Hagiwara S, Sourris K, Ziemann M, Tieqiao W, Mohan M, McClelland AD, Brennan E, Forbes J, Coughlan M, Harcourt B, Penfold S, Wang B, Higgins G, Pickering R, El-Osta A, Thomas MC, Cooper ME, Kantharidis P: RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis. Diabetes 67:960-973, 2018

研究者 教育活動